These are the most deadly pathogens — so why aren’t drug companies targeting them?
Despite calls to step up efforts, investment in antimicrobial resistance is still insufficient.
Tomas Kauer - Moderator 
Despite calls to step up efforts, investment in antimicrobial resistance is still insufficient.
